News

Merck held talks to buy biotech MoonLake for over $3 billion, FT reports
Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...
These Stocks Are Moving the Most Today: Nvidia, TSMC, Tesla, Constellation Energy, Credo, Dollar General, Moonlake, and More
Shares of Nvidia and Tesla edge higher, while Taiwan Semiconductor Manufacturing says it faces limited impact from global ...
Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report
Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...
Fierce Biotech4d
Merck made $3B-plus offer for MoonLake—and could revive interest in late-phase biotech: FT
Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...
Merck held talks to buy Swiss biotech MoonLake for more than $3bn
Despite the slowdown in dealmaking, French drugmaker Sanofi on Monday agreed to buy immunology-focused biotech Blueprint Medicines in a deal worth up to $9.5bn and Bristol Myers Squibb struck an up to ...
Merck & Co., Inc. (MRK) Held Talks Over $3 Billion Acquisition of Swiss Biotech Firm MoonLake
Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...
MoonLake Immunotherapeutics stock surges on FT report of Merck buyout talks
Investing.com -- Shares of MoonLake Immunotherapeutics soared 21.5% following reports that Merck (NSE: PROR) has engaged in discussions regarding a potential acquisition of the Swiss biotech firm for ...
The Business Times4d
Merck held talks to buy biotech MoonLake for over US$3 billion: FT
MERCK has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than US$3 billion, the Financial Times ...